Phosplatin Therapeutics Convenes Clinical Advisory Board with Prostate Cancer Experts During ESMO 2019 Annual Congress
BARCELONA, September 29, 2019 – Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today gathered industry experts during the European Society of Medical Oncology Annual Congress to review clinical data from prostate cancer sub-populations from Phase I studies of PT-112 monotherapy (PT-112-101) and combination with PD-L1 immune checkpoint inhibition (PT-112-103-PAVE-1), and to explore clinical development pathways for use of PT-112 in metastatic castration-resistant prostate cancer patients.
The newly constituted clinical development advisory board includes Alan H. Bryce, MD, Associate Professor of Medicine and Chair, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic Arizona; Howard I. Scher, MD, Co-Chair, Center for Mechanism Based Therapy, Head of the Biomarker Development Initiative, and D. Wayne Calloway Chair in Urologic Oncology, Memorial Sloan Kettering Cancer Center; Himisha Beltran, MD, Associate Professor of Medicine, Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology, and Director of Translational Research within Medical Oncology, Dana-Farber Cancer Institute; Scott T. Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine; and Daniel D. Karp, MD, Professor, Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, who has led both solid tumor Phase I studies of PT-112. This group of key opinion leaders will continue to work to refine the clinical development plan for PT-112. Phosplatin Therapeutics intends to initiate a Phase II clinical trial in metastatic castration resistant prostate cancer (mCRPC) patients in 2020.
“Building upon our translational research, Phase I studies of PT-112 in solid tumors have established clear feasibility and preliminary evidence of efficacy within the prostate cancer sub-populations treated during early development,” said Matthew R. Price, Executive VP & Chief Operating Officer at Phosplatin Therapeutics. “With the ongoing input of this esteemed panel of advisors, we believe we will maximize PT-112’s potential for addressing unmet medical needs among advanced, metastatic patients.”
About PT-112
PT-112 is the first small molecule conjugate of pyrophosphate developed in oncology therapeutics. PT-112 promotes immunogenic cell death (ICD), or the release of damage associated molecular patterns (DAMPs) that lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents a potential best-in-class small molecule inducer of this immunological form of cancer cell death, and is under Phase II development. The first-in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients, and won “Best Poster” at the ESMO 2018 Annual Congress within the Developmental Therapeutics category. The novelty of its pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in bone, or frequently lead to metastatic bone involvement, such as metastatic castrate-resistant prostate cancer (mCRPC).
About Phosplatin Therapeutics
Phosplatin Therapeutics is a private, clinical stage pharmaceutical company that holds the exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism. Clinical data generated to date across three Phase I studies have demonstrated single agent anti-cancer activity and an attractive tolerability profile. The company's research and development work to date has spanned fifteen countries and been funded by private investors and family investment offices in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company is also sponsoring an ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada).
CONTACTS:
Phosplatin Therapeutics
Taylor Young
Senior Director of Strategic Development
Tel: +1 646 380 2441
Email: tyoung@phosplatin.com
